Literature DB >> 8846004

Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis.

A Y Chiu1, P Zhai, M C Dal Canto, T M Peters, Y W Kwon, S M Prattis, M E Gurney.   

Abstract

The mutation gly93-->ala of Cu,Zn superoxide dismutase (SOD) is found in patients with familial amyotrophic lateral sclerosis and causes motor neuron disease when expressed in transgenic mice. The progression of clinical and pathological disease was studied in a line of mice designated G1H. Clinical disease started at 91 +/- 14 days of age with fine shaking of the limbs, followed by paralysis and death by 136 +/- 7 days of age. Pathological changes begin by 37 days of age with vacuoles derived from swollen mitochondria accumulating in motor neurons. At the onset of clinical disease (90 days), significant death of somatic motor neurons innervating limb muscles has occurred; mice at end-stage disease (136 days) show up to 50% loss of cervical and lumbar motor neurons. However, neither thoracic nor cranial motor neurons show appreciable loss despite vacuolar changes. Autonomic motor neurons also are not affected. Mice that express wild-type human Cu,Zn SOD remain free of disease, indicating that mutations cause neuron loss by a gain-of-function. Thus, the age-dependent penetrance of motor neuron disease in this transgenic model is due to the gradual accumulation of pathological damage in select populations of cholinergic neurons.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8846004     DOI: 10.1006/mcne.1995.1027

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  99 in total

Review 1.  Genotype to phenotype: challenges and opportunities.

Authors:  D P Holschneider; J C Shih
Journal:  Int J Dev Neurosci       Date:  2000-10       Impact factor: 2.457

Review 2.  Turning heads: development of vertebrate branchiomotor neurons.

Authors:  Anand Chandrasekhar
Journal:  Dev Dyn       Date:  2004-01       Impact factor: 3.780

Review 3.  Programmed cell death in amyotrophic lateral sclerosis.

Authors:  Christelle Guégan; Serge Przedborski
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

4.  Length-dependent axo-terminal degeneration at the neuromuscular synapses of type II muscle in SOD1 mice.

Authors:  C Tallon; K A Russell; S Sakhalkar; N Andrapallayal; M H Farah
Journal:  Neuroscience       Date:  2015-11-18       Impact factor: 3.590

Review 5.  Motor neuron trophic factors: therapeutic use in ALS?

Authors:  Thomas W Gould; Ronald W Oppenheim
Journal:  Brain Res Rev       Date:  2010-10-21

6.  The Psi(m) depolarization that accompanies mitochondrial Ca2+ uptake is greater in mutant SOD1 than in wild-type mouse motor terminals.

Authors:  Khanh T Nguyen; Luis E García-Chacón; John N Barrett; Ellen F Barrett; Gavriel David
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-27       Impact factor: 11.205

Review 7.  Mutant CuZn superoxide dismutase in motor neuron disease.

Authors:  M E Gurney; R Liu; J S Althaus; E D Hall; D A Becker
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

8.  Progressive changes in synaptic inputs to motoneurons in adult sacral spinal cord of a mouse model of amyotrophic lateral sclerosis.

Authors:  Mingchen Jiang; Jenna E Schuster; Ronggen Fu; Teepu Siddique; C J Heckman
Journal:  J Neurosci       Date:  2009-12-02       Impact factor: 6.167

9.  Astragaloside IV and echinacoside benefit neuronal properties via direct effects and through upregulation of SOD1 astrocyte function in vitro.

Authors:  Yang Tian; Shijie Jin; Vanessa Promes; Xuemei Liu; Yunling Zhang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-11-20       Impact factor: 3.000

10.  The Golgi apparatus of spinal cord motor neurons in transgenic mice expressing mutant Cu,Zn superoxide dismutase becomes fragmented in early, preclinical stages of the disease.

Authors:  Z Mourelatos; N K Gonatas; A Stieber; M E Gurney; M C Dal Canto
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.